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Introduction
Chondroitin sulfate (CS) is a glycosaminoglycan (GAG) found 
attached to a protein core to form a proteoglycan. Chondroitin 
sulfate proteoglycans (CSPGs) play an important role in the 
extracellular matrix in the central nervous system.1 In neuronal 
development and regeneration, CSPGs modulate a wide range 
of activities from cell adhesion and division to synaptic plastic-
ity and regeneration,2,3 and several studies have shown that the 
activity of CSPGs can be attributed to the sulfation pattern of the 
CS chains.4-6 Previous work has investigated the effects of the CS 
GAG in vitro both in solution or adsorbed onto a flat surface,7-10 
but few have examined its effects on neurite outgrowth in three-
dimensional gels.6,11,12
CS-based biomaterials have been developed for a variety 
of applications, including cartilage tissue engineering13,14 and 
wound healing.15 In many of these studies, CS is modified either 
for covalent cross-linking for gel synthesis or for incorporation 
into the scaffold; however, the chemical modification of CS can 
interfere with potential binding sites and reduce CS bioactivity. 
Other systems physically entrap CS within the matrix, and dif-
fusion of CS is controlled by the physical properties of the bio-
material.16 Other GAGs have been incorporated into hydrogels 
as well, and in some cases, these have been added by integrating 
GAG-binding domains into the biomaterial. Sakiyama-Elbert 
et al. have developed an affinity-based system where heparin 
was incorporated in fibrin matrices through heparin-binding 
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peptides.17,18 This group has also shown that growth factor activ-
ity can be regulated by GAG-binding through sequestration and 
localization of growth factor activity.19 Sakiyama-Elbert et al. 
have improved neurite outgrowth both in vitro20-22 and in vivo23 
through affinity-based delivery of neurotrophins.
Our lab has developed a poly(ethylene glycol)(PEG)-co-
peptide polysaccharide system that has tunable viscoelastic and 
biological properties, as seen in Figure 1.24-27 In earlier studies, 
we incorporated heparin in the system in order to bind cell-pene-
trating peptides. In the current study, we have modified the mate-
rial specifically to incorporate CS and take advantage of native 
interactions between CS and nerve growth factor (NGF) for 
controlled release. The mechanical properties of this material are 
controlled both through physical interactions of GAG-binding 
peptides, covalently bound to eight-arm PEG, with GAGs and 
through the cross-linking of eight-arm PEG (black lines) with 
bi-functional enzymatically degradable cross-linking peptides 
(dark gray dumbbells) that include an integrin-binding sequence 
(RGD). Unmodified CS (striped stars) is entrapped within the 
biomaterial through interactions with CS-binding peptides (light 
gray hexagons) conjugated to eight-arm PEG. Finally, CS provides 
binding sites for the incorporation of NGF (spotted triangles).
In earlier work, we demonstrated the viability of chondroitin-
6-sulfate (C6S)-based scaffolds to support outgrowth of dorsal 
root ganglia (DRGs) in vitro.28 Thus, this system has potential 
for use as a therapeutic implantable hydrogel to promote regen-
eration of neurons in traumatic root avulsion brachial plexus 
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the addition of C6S and BP significantly affected the viscoelastic 
properties of the gels.
From the frequency sweep, 10 rad/s was chosen from the lin-
ear viscoelastic range, and a time sweep was performed at 0.5% 
strain for 6 min. Figure 3 shows the averaged complex modulus 
for the different gel compositions. At 10 rad/s and 0.5% strain, 
the PEG gel (100 Pa) was significantly (p < 0.05) stronger than 
all other gels with C6S and/or BP. The weakest gel (~38 Pa) con-
tained both BP and C6S (PEG-BP-C6S) and was not statistically 
different (p > 0.05) from gels that contained either C6S (PEG-
C6S) or BP (PEG-BP). These results demonstrate that PEG gels 
that contain either BP or C6S are significantly weaker than gels 
without BP or C6S.
To demonstrate that inclusion of C6S would provide a con-
trolled release mechanism, studies were done to investigate NGF 
release from the various gel compositions shown in Table 1. The 
amount of NGF released over 48 h was quantified with an ELISA 
kit. As negative controls, NGF release from gels without C6S and/
or BP was monitored to determine if C6S and BP affected NGF 
release from PEG gels. The release profiles of the gels are shown in 
Figure 4. PEG gels that contained only C6S (PEG-C6S) had the 
fastest NGF release, while gels that contained both BP and C6S had 
the slowest release profile (PEG-BP-C6S). The two-way ANOVA 
analysis showed that the addition of BP to PEG gels was a signifi-
cant factor affecting NGF release, whereas C6S was not. Table 2 
shows the results from the post-hoc test to determine significance 
of NGF release between gels at different time points (0–48 h). At 
earlier time points (0–7 h), the amount of NGF released from the 
PEG-C6S gel is significantly greater than NGF released from gels 
with the BP (Table 2, light shading). At later time points (4–48 h), 
NGF release is significantly slower in PEG-BP-C6S than in all 
other gels (Table 2, dark shading). These results show that PEG 
gels that contain only BP have a slower NGF release profile when 
compared with PEG controls, while gels that contain both BP and 
C6S demonstrate the slowest NGF release profile.
injuries. However, regeneration in these injuries will require 
both peripheral and central nerve growth, and previous studies 
have revealed that C6S inhibits the regeneration of central neu-
rons.29 This lack of central nervous system neuronal growth will 
likely prevent successful reintegration of the central and periph-
eral nervous systems if a C6S-based material were implanted in 
an in vivo model. Incorporation of the C6S-binding peptide 
described in previous work and investigated in the current work 
may help block these inhibitory signals and promote recovery 
after traumatic root avulsion brachial plexus injuries.29,30
To validate, in vitro, the potential use of this system as a 
therapy, we investigated the controlled release of NGF from 
this C6S-based biomaterial. In addition, we investigated the 
effects of NGF release on primary cortical neurite outgrowth. 
Controlled release of NGF is achieved via non-covalent interac-
tions between NGF, CS and CS-binding peptide. Neurite out-
growth was inhibited on gels that only included C6S, but this 
inhibition was overcome when NGF was incorporated into the 
gel.
Results
To investigate the effect peptide and CS incorporation into PEG 
gels had on the viscoelastic properties of gels, the compositions 
shown in Table 1 were investigated using rheology. As negative 
controls, gels without C6S and/or BP (binding peptide) were 
tested. Figure 2 shows the complex modulus (G*) for the differ-
ent gel compositions at 0.5–50 rad/s frequency and 0.5% strain. 
The PEG gel without C6S and BP (PEG) was the strongest, 
while the PEG gel with C6S and BP (PEG-BP-C6S) was the 
weakest. The two-way repeated measures ANOVA showed that 
Figure 1. Affinity-based NGF delivery from peG-co-peptide CS system. 
eight-arm peG (black lines) are modified with bi-functional cross-linking 
peptides (dark gray dumbbells) on 6 arms and CS-binding peptides 
(light gray hexagons) on 2 arms. CS (striped stars) interacts with CS-
binding peptides and NGF (spotted triangles).
Table 1. Gel compositions
Gel name C6S-binding C6S NGF
Rheology
peG   
peG-C6S   
peG-Bp   
peG-Bp-C6S   
NGF Release
peG-NGF   
peG-C6S-NGF   
peG-Bp-NGF   
peG-Bp-C6S-NGF   
Cotical Cell Culture
peG-Bp   
peG-Bp-C6S   
peG-Bp-NGF   
peG-Bp-C6S-NGF   
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that included C6S-binding peptide and/or C6S were weaker than 
PEG gels without C6S and C6S-binding peptide. The cross-link-
ing reaction of the bi-functional peptides with PEG-maleimide 
(Mal) is extremely fast. It is possible that C6S and C6S-binding 
peptides, which were added to the PEG-Mal solution before 
cross-linking, act as physical barriers between cross-linking sites 
on different eight-arm PEG molecules, leading to decreased 
intermolecular cross-linking and weaker gels. It is also possible 
that after conjugation of two C6S-binding peptides to the star 
polymer, the efficiency of the cross-linking of the remaining six 
arms is reduced. Indeed, when C6S and C6S-binding peptide are 
both incorporated into gels, the PEG gels are the weakest. Further 
studies are needed to elucidate why cross-linking is suppressed.
To examine the effects of C6S, BP 
and controlled NGF release from the 
gels on neurite outgrowth, cortical neu-
rons were cultured on PEG gels of differ-
ent compositions (Table 1) for 48 h. The 
average and maximum length and num-
ber of neurites was quantified for each 
neuron. Approximately 80–200 neurons 
were analyzed for each gel composition. 
Figure 5 shows (1) the average neurite 
length, (2) maximum neurite length 
(3) and number of neurites for each gel 
composition. Controls consisted of neu-
rons cultured on PEG gels that did not 
include C6S and/or NGF. PEG gels that 
included only C6S (PEG-C6S) had lower 
average/maximum neurite length and 
number of neurites compared with PEG 
gels without C6S (PEG-BP). Therefore, 
C6S in PEG gels inhibits neurite 
outgrowth.
When NGF was incorporated into 
PEG gels (PEG-BP-NGF), the average 
and maximum neurite lengths were sig-
nificantly higher than gels without NGF 
(PEG-BP and PEG-BP-C6S). In gels 
with C6S, the neurite length with NGF 
(PEG-BP-C6S-NGF) was significantly 
higher than gels without NGF (PEG-BP 
and PEG-BP-C6S). These results (Fig. 
5A and B) show that NGF incorporation 
into PEG gels not only stimulates neurite 
growth, but also overcomes the inhibitory 
effects of C6S.
Neurons cultured on PEG-BP-NGF 
had the same number of neurites as neu-
rons cultured on PEG-BP. Furthermore, 
neurons cultured on PEG-BP-C6S-NGF 
had the same number of neurites as neu-
rons cultured on PEG-C6S (Fig. 5C). 
Therefore, NGF had no effect on the 
number of neurites. The results from cor-
tical neuron culture on PEG gels (Fig. 5) 
showed that C6S decreased neurite out-
growth, while NGF increased neurite length.
Discussion
The PEG-co-peptide polysaccharide biomaterial developed by 
Seal and Panitch24-26 is a model system to investigate the effects of 
affinity-based delivery of biological molecules on cortical neuron 
behavior. In this study, we modified the PEG-co-peptide poly-
saccharide system by incorporating C6S through C6S-binding 
peptides conjugated to eight-arm PEG rather than using heparin 
and heparin-binding peptides as done in the original materials. 
Rheological results shown in Figure 1 demonstrate that PEG gels 
Figure 2. Frequency sweep (0.5–500 rad/s) of gels at 0.5% strain. peG gels without C6S or Bp had 
the highest viscoelastic properties while gels with C6S and/or Bp had significantly lower complex 
moduli. Mean ± Se.
Figure 3. time sweep of peG gels at 10 rad/s and 0.5% strain. peG gels that contained C6S and/
or Bp had significantly lower complex moduli than gels without C6S or Bp. Mean ± Se, *p < 0.05 
different relative to peG.
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after photobleaching studies dem-
onstrated that C6S gels containing 
this C6S-binding peptide exhibited 
lower NGF diffusivity when com-
pared with gels with C6S only.30
One of the goals of the cur-
rent study was to investigate the 
effects of C6S immobilized in 
gels on cortical neuron behavior. 
Previous studies showed that DRG 
neurite extension is inhibited by 
chondroitin-4,6-sulfate6 and der-
matan sulfate12 immobilized in 
agarose gels, however, the CS used 
in these studies was modified for 
covalent attachment, which may 
interfere with CS-cell interactions. 
Therefore, the PEG-peptide poly-
saccharide system described in the 
current study is an ideal biomate-
rial for investigating the effects of 
unmodified CS in gels. Primary 
cortical neurons were used in this 
study to model cellular behavior following injury to the central 
nervous system.31 Results showed that neurite length and number 
of neurites were significantly lower in gels with C6S compared 
with gels without C6S and demonstrate that C6S in PEG gels 
inhibits cortical neurite outgrowth.
CS can influence cell behavior not only through direct inter-
action, but also indirectly, through growth factor modulation.19,32 
Thus, another goal of this study was to investigate whether the 
addition of NGF to the system could overcome the inhibitory 
effects of C6S; this was motivated by studies by Zhou et al. that 
showed that NGF promotes DRG growth over CSPG-coated 
slides.33-35 In the current study, the effects of C6S and NGF in 
gels on cortical neurons were investigated. In PEG gels with only 
NGF, the average and maximum neurite length was significantly 
greater than in PEG gels without NGF. This result agrees with 
previous studies that demonstrate the growth-promoting effects 
of NGF both in vitro and in vivo.34,35 In PEG gels with C6S 
and NGF, the neurite length was significantly greater than PEG 
gels without C6S and NGF. However, the number of neurites in 
The mechanical strength of the gels may affect NGF release 
from the PEG gels. In the NGF release assay, PEG gels with only 
C6S and no C6S-binding peptide had the fastest NGF release. 
Since these gels are weaker than PEG gels without C6S, it is 
likely that the cross-link density is decreased, thus increasing the 
molecular weight between cross-links and the average pore size. 
NGF could have quickly diffused out of the larger pores that 
are characteristic of lower cross-link density gels. The NGF assay 
also showed that PEG gels with C6S and C6S-binding peptide 
released NGF the slowest compared with all other gels. Although 
the PEG-BP-C6S gel was the most compliant, the binding 
between NGF, C6S and C6S-binding peptide was strong enough 
to prevent rapid diffusion from the weaker gel. These results 
show that C6S and the C6S-binding peptide are both impor-
tant for slow diffusion of NGF from PEG gels and, possibly, 
point to a synergistic NGF-binding activity between C6S and 
the C6S-binding peptide, since NGF release was slowest when 
gels contained both of these molecules. This hypothesis is sup-
ported by other work with C6S gels, where fluorescence recovery 
Table 2. Summary of post-hoc test of NGF release from different gels
Time (hrs)b
Gels with NGFa 0 2 4 7 18 32 48
peG Bp-C6S Bp-C6S Bp-C6S Bp-C6S Bp-C6S Bp-C6S
peG-C6S 
(C6S)
Bp 
Bp-C6S
Bp 
Bp-C6S
Bp 
Bp-C6S
Bp 
Bp-C6S
Bp-C6S Bp-C6S Bp-C6S
peG-Bp 
(Bp)
C6S C6S
C6S 
Bp-C6S
C6S 
Bp-C6S
Bp-C6S Bp-C6S Bp-C6S
peG-Bp-C6S 
(Bp-C6S)
C6S C6S    peG all other gels all other gels all other gels all other gels all other gels
aGel compositions with NGF. bAt each time point, the gel that is statistically significant (p < 0.05) from the gel composition in the left column is listed.
Figure 4. NGF release profile of gels with and without Bp and C6S. NGF release was monitored over 48 h. 
After 2 d, the gels were digested and the amount of NGF quantified. peG gels that include Bp and C6S had 
the slowest release while peG gels that only had C6S had the fastest release. Mean ± Se.
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Figure 5. effect of C6S and NGF on cortical neuron outgrowth. Neurons were cultured on gels with and without C6S and/or NGF for 48 h. the average 
neurite length (A), maximum neurite length (B), and number of neurites (C) were determined for each gel composition. Mean ± Se, *p < 0.05 relative to 
peG-Bp, #p < 0.05 relative to peG-Bp-C6S, +p < 0.05 relative to peG-Bp-NGF.
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0848-10) and centrifuged at 5,000 rpm for 30 min. The ether 
was decanted off and the peptide was resolubilized in water 
before lyophilization.
Peptide purification was performed using reverse phase chro-
matography with an ÄKTA Explorer system (GE Healthcare) 
equipped with a C18 column (Grace Vydac; 22 mm internal 
diameter, 250 mm length, 10–15 μm particle size). After the col-
umn was equilibrated with 5 column volumes of water contain-
ing 0.1% trifluoroacetic acid, the peptide was loaded onto the 
column and subjected to an increasing linear gradient from 0 to 
60% of acetonitrile (Sigma-Aldrich, 34998) containing 0.1% tri-
fluoroacetic acid over 12 column volumes. The collected peptides 
were lyophilized, and the mass of each peptide was confirmed 
with matrix-assisted laser desorption/ionization-time of flight 
mass spectrometry on a Voyager-DE STR spectrometer (Applied 
Biosystems).
C6S-binding peptides were conjugated to maleimide-func-
tionalized eight-arm PEG-Mal (MW ~40,000 g/mol, Nektar 
Therapeutics) following a modified version of previous stud-
ies in references 24–27. Peptides were conjugated to PEG-Mal 
through a Michael-type addition in 1x PBS (pH 7.4, Invitrogen, 
14040182) containing 2 mM EDTA (Sigma-Aldrich, E6758). 
Two arms were conjugated with C6S-binding peptide, while 
the other six arms were cross-linked with enzymatically degrad-
able bi-functional cross-linking peptide. First, the C6S-binding 
peptide was conjugated to PEG-Mal by preparing a 2% (w/v) 
solution of PEG-Mal and C6S-BP at 2-molar excess of eight-arm 
PEG. The solution was incubated in the dark at room tempera-
ture for 1 h. After conjugation, the PEG-co-C6S-BP solution was 
kept in the dark on ice.
A 2% (w/v) solution of C6S (Sigma-Aldrich, C4384) was 
added in a 1:4 molar ratio of C6S to PEG-co-peptide. Finally, 
the bi-functional cross-linking peptide (xlinker) in a 2% (w/v) 
solution was added in a 3:1 molar ratio of PEG or PEG-BP. The 
gels were allowed to cross-link for 1 h at room temperature. 
Table 1 shows the gel compositions used in this study.
The viscoelastic properties of the hydrogels were measured 
with a Physica MCR 101 rheometer (Anton Paar) using a 
parallel-plate geometry with a 20 mm diameter and 100-μm 
gap. The temperature of the rheometer surface was controlled 
at 20°C with a built-in Peltier system. To prevent evaporation 
of the sample, an evaporation-blocking chamber was lowered 
over the sample. Gels (100 μl) were prepared in triplicate and 
tested with a frequency and time sweep. The linear range of 
the viscoelastic response was first measured with a frequency 
sweep from 0.5–50 rad/s at 0.5% strain. The time sweep was 
performed at an angular frequency of 10 rad/s and 0.5% strain 
for 6 min. The complex modulus (G*) of each gel was calcu-
lated by averaging the G* over time. To determine the effects 
of the C6S-binding peptide and C6S on the viscoelastic prop-
erties of the material, gels were tested with and without BP 
and C6S.
The amount of NGF released from gels with and without 
the C6S-binding peptide and C6S was quantified. Gels (50 μl) 
were prepared in triplicate in 2 ml siliconized tubes, as previously 
described, that contained 2 μg/ml NGF (Invitrogen, 13257019). 
PEG gels with C6S and NGF was significantly less than PEG 
gels without C6S and NGF. Therefore, NGF can overcome the 
inhibitory effects of C6S for neurite extension but not for neurite 
branching and outgrowth, resulting in neurons with fewer and 
longer neurites. Furthermore, it has been shown that addition of 
the C6S-binding peptide to matrices of C6S boosts their ability 
to support DRG growth, possibly through enhanced sequestering 
of NGF inside the hydrogel and blocking of any potential C6S 
inhibition.30
In general, C6S inhibits neurite outgrowth and acts as a bar-
rier for axon connections during development and after spinal 
cord injury. It is hypothesized that C6S provides an inhibitory 
substrate with which growth-promoting molecules, such as 
growth factors, can adhere, and provide guidance cues for neurite 
extension and connection.32 Therefore, the PEG-peptide polysac-
charide system that incorporates C6S and NGF through non-
covalent interactions is an ideal model for the developing central 
nervous system.
One of the goals of neural tissue engineering is to promote 
axonal regeneration for functional recovery. Often, the use of 
NGF and other growth-promoting molecules causes an uncon-
trolled increase in neurite outgrowth, which can lead to super-
fluous connections that cause side effects, such as neuropathic 
pain.36 Therefore, it is important that for neural tissue engineer-
ing, the biomaterial must not only encourage neurite outgrowth 
but also provide guidance cues for meaningful connections.37 In 
this study, C6S provides an inhibitory background while NGF 
promotes neurite outgrowth leading to fewer longer neurites. 
Future studies will pattern NGF on C6S substrates to guide neu-
rite growth for functional connections.
Materials and Methods
The C6S-binding peptide was identified through peptide array 
screening in a previous study in reference 38. The peptides 
listed in Table 3 were synthesized through standard Fmoc-
solid phase chemistry on a Symphony peptide synthesizer 
(Protein Technologies, Inc.) at 200 μM with rink amide resin 
(Anaspec, 20084). Fmoc-protected amino acids were activated 
by O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexa-
fluorophosphate (Synbiosci, REAG2) and added to the grow-
ing peptides in 5 M excess. After peptide synthesis, the peptides 
were cleaved from the resin using a cleave cocktail containing 
92.5% triflluoroacetic acid (Acros Organics, 139725000), 2.5% 
water, 2.5% triisopropylsilane (TCI America, T1533), and 2.5% 
ethanedithiol (Alfa Aesar, L12865). Peptides were precipitated 
in 10x excess ice-cold diethyl ether (Mallinckrodt Chemicals, 
Table 3. peptide summary
Peptide 
name
Peptide function Peptide sequence
Bp C6S-binding peptide eKRIWFpYRRFGC
xlinker
bi-functional enzymatically 
degradable cross-linking 
peptide
GCR GDS GpQ GIA 
GQG C
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again washed 3x and blocked overnight with 1% bovine serum 
albumin (BSA, Sigma-Aldrich, A7906) and 10% goat serum 
(Invitrogen, 50062Z). After blocking, the cells were washed 6x 
with 0.1% BSA in PBS then incubated in 5 μg/ml mouse anti-
βIII-tubulin (R&D Systems, MAB1195) at room temperature 
for 2 h and overnight at 4°C. The cells were again washed 3x 
with 0.1% BSA in PBS and incubated in 2 μg/ml Alexa-488-
coupled goat anti-mouse F(ab)’
2
-fragment secondary antibody 
(Invitrogen, A11029) for 2 h at room temperature in the dark. 
Finally, the cells were washed 3x with 0.1% BSA in PBS before 
visualization.
Images were captured using a Leica DMIRB (Leica 
Microsystems) epifluorescence microscope. A USH-102DH-
100W ultra-high-pressure mercury lamp (USHIO America, 
Inc.,) was used as the excitatory light source. Images were viewed 
in the blue excitation range (filter set I3-excitation filter BP450–
490 nm and emission filter BP515 nm) with a 20x objective. 
The images were analyzed with a custom Matlab program that 
measured the distance of each neurite from the center of the cell 
body. Approximately 100–200 neurons were analyzed for each 
treatment.
Statistical analysis was performed with Minitab 15 (Minitab) 
and SPSS 16 (SPSS). A one-way ANOVA and Tukey’s post-hoc 
test (α = 0.05) was performed to determine statistical signifi-
cance (p < 0.05) of the G* of the different gels for the time sweep. 
Repeated measures of two-factor ANOVA (α = 0.05) were per-
formed to determine statistical significance (p < 0.05) of the G* of 
the different gels for the frequency sweep and of the NGF release 
of the different gels. A Tukey’s post-hoc test (α = 0.05) was per-
formed to determine significance of different gels at 10 rad/s for 
rheology and at 0 to 48 h for the NGF release assay. To determine 
differences in cortical neuron outgrowth, a Kruskal-Wallis with a 
Mann-Whitney post-hoc test (α = 0.05) was performed.
Conclusions
In this study, the effects of affinity-based delivery of C6S and 
NGF from gels on cortical neurite behavior were investigated. 
C6S and NGF were incorporated into PEG gels through C6S-
binding peptides. Gels with C6S inhibited neurite outgrowth, 
while gels with NGF promoted neurite extension. The inhibitory 
activity of C6S was overcome by NGF, which was slowly released 
from PEG gels through non-covalent interactions between C6S-
binding peptide, C6S and NGF. The affinity-based system devel-
oped in this study that incorporates C6S and NGF is an ideal 
biomaterial for studying neural development and for neural tissue 
engineering.
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After the gels were cross-linked, 2 ml of 1x PBS was added onto 
each gel. At each time point, 500 μl of buffer was collected from 
each tube and immediately replaced with 500 μl of buffer using 
siliconized pipets and tubes. NGF release was monitored over 
48 h, and samples were stored at -20°C. After 2 d, the gels were 
broken up with a spatula and digested in 10 units/ml collagenase 
and 0.4 units/ml chondroitinase ABC (Sigma-Aldrich, C3667) 
for 48 h at 37°C with gentle shaking. The amount of NGF in the 
collected samples was quantified with a human β-NGF ELISA 
development kit (Peprotech, 900-K60). The absorbance of each 
well was measured at 405 nm and 650 nm after 10 min of incu-
bation with ABTS liquid substrate (Sigma-Aldrich, A3219) on a 
multi-well plate reader (FLUOstar Omega, BMG Labtech). The 
absorbance at 650 nm was subtracted from the absorbance at 405 
nm to determine the relative absorbance of each well, and the 
amount of NGF was calculated from a standard curve.
To determine the biological activity of C6S and NGF, cortical 
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2
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